SHOW US THE MONEY

By Peter GwynneSHOW US THE MONEYDespite limited sources of capital, would-be entrepreneurs with solid biobusiness ideas can usually obtain financial support.Art PappasJASON VARNEY | VARNEYPHOTO.COMIt might lack the intellectual cachet of life science in Boston-Cambridge and the Bay area, but North Carolina boasts a significant amount of research in biomedical fields. The work consistently produces both intellectual property and scientist-entrepreneurs eager to exploit it by forming startup compa

Written byPeter Gwynne
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

It might lack the intellectual cachet of life science in Boston-Cambridge and the Bay area, but North Carolina boasts a significant amount of research in biomedical fields. The work consistently produces both intellectual property and scientist-entrepreneurs eager to exploit it by forming startup companies. However, the state faces a significant shortage of traditional sources of startup funds. "The ratio of research dollars to venture capital dollars in North Carolina and the southeast is higher than elsewhere in the country," says Garheng Kong, general partner at Durham-based venture capital (VC) company, Intersouth Partners.

Nonetheless, most life scientists in North Carolina who want to take their research to market have been able to find sufficient startup support. Universities, state-government centers, VC companies, and even firms in the life science industry have provided the early money that promises to make North Carolina a significant starter of new businesses in biopharma and biotechnology.

"We're ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies